Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Brienza

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Substance Abuse Treatment|May 17, 2000
Depression among needle exchange program and methadone maintenance clientsR S Brienza, M D Stein, M Chen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
An oriented phase II trial of THP-adriamycin in breast carcinomaG Mathé, H Umezawa, S Oka, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Journal of the National Cancer Institute|June 20, 1990
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rateJ P Caussanel, F Lévi, S Brienza, et al.
Archivos De Bronconeumologia|May 26, 2009
[Development of a murine model of airway inflammation and remodeling in experimental asthma]Rebeca Fraga-Iriso, Laura Núñez-Naveira, Nadia S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rateF Levi, B Perpoint, C Garufi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP)G Mathé, Y Kidani, K Triana, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1989
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinumG Mathé, Y Kidani, M Segiguchi, et al.
British Journal of Cancer|August 17, 2001
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsM A Bensmaïne, M Marty, A de Gramont, et al.
Clinical Pharmacology and Therapeutics|August 1, 1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancerG Metzger, C Massari, M C Etienne, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Substance Abuse Treatment|May 17, 2000
Depression among needle exchange program and methadone maintenance clientsR S Brienza, M D Stein, M Chen, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
An oriented phase II trial of THP-adriamycin in breast carcinomaG Mathé, H Umezawa, S Oka, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Journal of the National Cancer Institute|June 20, 1990
Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rateJ P Caussanel, F Lévi, S Brienza, et al.
Archivos De Bronconeumologia|May 26, 2009
[Development of a murine model of airway inflammation and remodeling in experimental asthma]Rebeca Fraga-Iriso, Laura Núñez-Naveira, Nadia S Brienza, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rateF Levi, B Perpoint, C Garufi, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1986
A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP)G Mathé, Y Kidani, K Triana, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 1, 1989
Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinumG Mathé, Y Kidani, M Segiguchi, et al.
British Journal of Cancer|August 17, 2001
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patientsM A Bensmaïne, M Marty, A de Gramont, et al.
Clinical Pharmacology and Therapeutics|August 1, 1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancerG Metzger, C Massari, M C Etienne, et al.
Pageof 6